Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial 70S ribosome subunit interface is the critical contact area between the 30S small subunit and the 50S large subunit, mediated by a series of dynamic intersubunit bridges (Liu & Fredrick, 2016). These bridges, primarily formed by ribosomal RNA (rRNA) and some ribosomal proteins, are essential for the assembly of the functional 70S ribosome and its conformational changes during protein synthesis (Yusupov et al., 2001). This interface serves as a major therapeutic target for several classes of antibiotics that disrupt bacterial translation (Wilson, 2014). For instance, oxazolidinones like linezolid bind to the 50S subunit at the interface to prevent the formation of the 70S initiation complex (Swaney et al., 1998). Other antibiotics, such as aminoglycosides and tuberactinomycins, bind near the interface to stabilize or destabilize subunit interactions, leading to misreading of the genetic code or inhibition of translocation (Wang et al., 2012). Because the bacterial 70S ribosome is structurally distinct from the eukaryotic 80S ribosome, these drugs exhibit selective toxicity. However, structural similarities with human mitochondrial ribosomes can lead to clinical side effects like ototoxicity and nephrotoxicity (Böttger et al., 2001). Targeting the interface remains a robust strategy for developing new antimicrobials to combat multi-drug resistant bacterial strains.
Inhibition of 70S initiation complex formation, stabilization of intersubunit bridges to prevent translocation, and interference with ribosomal subunit association and dissociation cycles (Wilson, 2014; Swaney et al., 1998).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 70S ribosome subunit interface (70S interface).